The effects of memantine on prepulse inhibition. [PDF]
, 2009 Reduced prepulse inhibition (PPI) of startle provides evidence of deficient sensorimotor gating in several disorders, including schizophrenia. The role of NMDA neurotransmission in the regulation of PPI is unclear, due to cross-species differences in the
Bergsma, F +4 more
core +2 more sources
Neurology and Therapy, 2023 Introduction This multicentre, randomised, open-label, and prospective study aimed to evaluate the effectiveness of memantine (memantine solution) on speech function in patients with moderate to severe Alzheimer’s disease (AD) who were already on ...
Hee-Jin Kim +11 more
doaj +1 more source
Memantine Disrupts Motor Coordination through Anxiety-like Behavior in CD1 Mice
Brain Sciences, 2022 Memantine is an FDA approved drug for the treatment of Alzheimer’s disease. It reduces neurodegeneration in the hippocampus and cerebral cortex through the inhibition of extrasynaptic NMDA receptors in patients and mouse models.
Anton N. Shuvaev +10 more
doaj +1 more source
Memantine for prevention of migraine: a retrospective study of 60 cases. [PDF]
, 2007 The objective was to retrospectively characterise the efficacy of memantine as preventive therapy in a series of patients with frequent migraine. Patients in a university headache clinic completed a survey regarding their experience with memantine, and ...
Brennan, Kevin C +3 more
core +1 more source
Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial. [PDF]
, 2016 Progressive cognitive deficits are common in patients with fragile X-associated tremor/ataxia syndrome (FXTAS), with no targeted treatment yet established.
Avar, Merve +9 more
core +2 more sources
Botulinum toxin for the treatment of lower limb cramp pain in patients with Amyotrophic Lateral Sclerosis [PDF]
, 2020 Background: Muscle cramps and pain associated with them can be seen in patients with amyotrophic lateral sclerosis (ALS) and are known to reduce the quality of life. Pharmacological treatment may not benefit all patients in treating these cramps.
Govindarajan, Raghav +2 more
core +2 more sources
Neuromodulation: Technology at the Neural Interface, EarlyView., 2021 Abstract Objectives Obsessive–compulsive disorder (OCD) is a psychiatric disorder with alterations of cortico‐striato‐thalamo‐cortical loops and impaired performance monitoring. Electrophysiological markers such as conflict‐related medial frontal theta (MFT) and error‐related negativity (ERN) may be altered by clinically effective deep brain ...
Elena Sildatke +9 more
wiley +1 more source
Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal–CA1 projection
BMC Neuroscience, 2021 Background Memantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate receptor antagonist, has been shown to improve cognitive functions in animal models of Alzheimer’s disease (AD).
Peng Li +5 more
doaj +1 more source
Contribution of Lysosome and Sigma Receptors to Neuroprotective Effects of Memantine Against Beta-Amyloid in the SH-SY5Y Cells [PDF]
Advanced Pharmaceutical Bulletin, 2020 Purpose: Memantine is an approved drug for the treatment of Alzheimer’s disease (AD). Autophagy, lysosome dysfunction, and sigma receptors have possible roles in the pathophysiology of AD.
Mojtaba Keshavarz +3 more
doaj +1 more source
Effects of memantine on the excitation-inhibition balance in prefrontal cortex
Neurobiology of Disease, 2016 Memantine is one of the few drugs currently approved for treatment of Alzheimer's disease (AD). The clinical effects of memantine are thought to be associated with inhibition of NMDA receptors (NMDARs).
Nadezhda V. Povysheva, Jon W. Johnson
doaj +1 more source